Warner Pharmaceutical Factory (688799.SH): The preparation work for the Phase III clinical trial of Class 1 innovative traditional Chinese medicine Ganqing granules has been fully launched.

Zhixin Financial News APP, Warner Pharmaceutical Factory (688799.SH) disclosed a notice of abnormal stock trading fluctuations. As of the disclosure date of the announcement, in the field of innovative drug research and development, the company's research on traditional Chinese medicine innovative drug Ganqing Granules has successfully completed Phase II clinical trials, and preparations for Phase III clinical trials have been fully launched. The ZG series products conducted on the project platform of its subsidiary Shanghai Zhigen Medical Technology Co., Ltd., ZG-001, are currently undergoing Phase IIa clinical trials, and it is expected to complete Phase IIa clinical trials this year. Based on the progress of clinical trials, Phase IIb clinical trials will be conducted. The ZG-002 project is currently undergoing Phase I clinical trials, expected to complete Phase I clinical trials this year, and Phase II clinical trials will be conducted based on the progress of the clinical trials. The research work of the endangered animal medicinal alternatives development project launched on the project platform of its subsidiary Hunan Tianji Rare Chinese Medicinal Materials Development Co., Ltd. is steadily progressing under the clear background of relevant review and approval policy guidelines. Among them, the ZY022 project is expected to complete the IND application this year and enter the Phase I clinical trial stage.